Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Many adult patients in chronic hemodialysis exhibit malnourishment and muscle wasting, which in some may be due partly to blockage of the biological action of growth hormone and the somatomedines.

Who Took Part

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

The study was double-blinded, randomized, and placebo-controlled.

Serum concentration of insulin-like growth factor (IGF-I) and type III collagen N-terminal propeptide (PIIINP) were analyzed at baseline and after 2, 4 and 6 months.

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Body Composition, Human Growth Hormone, Insulin-Like Growth Factor I, Kidney Failure, Chronic and Renal Dialysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Clinical nephrology), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.